10x Genomics, Inc. Stock News

PLEASANTON, Calif. , April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first q

Began global shipments for Visium HD, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution  PLEASANTON, Calif. , March 26, 2024 /PRNewswire/ -- 10x Genom

Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue

The next generation of the company's leading single cell technology architecture, GEM-X, enables higher performance at larger scale and lower cost PLEASANTON, Calif. , March 13, 2024 /PRNewswire/ -- 1

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen announces the denial of 10x Genomics' petition for Inter Partes Review of the Vizgen-licensed patent asserted against 10x's Xenium Platform.

The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifeti

Ark Invest bought shares of Roku, 10x Genomics, and Intellia Therapeutics on Monday. Roku has shed more than one-third of its value over the past two weeks after a series of unfortunate events.

PLEASANTON, Calif. , Feb. 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate

10x Genomics, Inc. (TXG) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall

10x Genomics (TXG) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.15 per share a year ago.

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10x Genomics reported 18% YoY revenue growth in Q4, reaching $184M, with instruments revenue seeing a remarkable surge of 71%. The company celebrated the successful launch of its cutting-edge platform

10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. The company has

10x Genomics, Inc. (NASDAQ:TXG ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Cassie Corneau - Director, Investor Relations and Strategic Finance Serge Saxonov - C